JAK1 and vitiligo: It was challenging to test the therapeutic efficacy of si3033 administered after disease manifestation in this model because the accelerated autoimmunity in the early stage of vitiligo progression overpowers the delayed effects of si3033 (maximum JAK1 silencing required 1–2 weeks), thereby interfering with final therapeutic readouts.